Loren Data's SAM Daily™

FBO DAILY ISSUE OF MARCH 24, 2004 FBO #0849
SOLICITATION NOTICE

B -- Support for Research on Retroviral Pathogenesis, Treatment and Prevention

Notice Date

3/22/2004
 

Notice Type

Solicitation Notice
 

NAICS

541940 — Veterinary Services
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

N02-RC-47008-74
 

Response Due

5/10/2004
 

Archive Date

5/25/2004
 

Point of Contact

Odessa Henderson, Contract Specialist, Phone (301) 435-3812, Fax (301) 402-6699,
 

E-Mail Address

oh4o@nih.gov
 

Description

The National Cancer Institute (NCI)is soliciting proposals from offerors with the capacity to provide on-going support for the Section on Animal Models and Retroviral Vaccines and the Section on Immune Biology of Retrovial Infection of the Center for Cancer Research which will include investigations related to development of vaccines for prevention of retroviral infection, development of treatment strategies for AIDS, and elucidation of mechanisms of retroviral pathogenesis. The proposed project will provide research support in several areas including cell culture and virology, immunology, protein biochemistry, and molecular biology. All these areas are critical to thorough study of retroviral pathogenesis and evaluation of candidate vaccines. A culture capability will provide for virus isolation and characterization, and development and expansion of viral stocks, critical for assessment of infection following challenge of vaccinated animals with live viruses, for studies of viral variation and evolution, for identification of novel viruses, and for provision of essential viral strains for use in vitro and in vivo. An immunologic capability will provide support in evaluating seroprevalence of viruses of interest and immune responses elicited by candidate vaccines, and in determining immune parameters associated with protection from viral infection or disease progression. A virologic capability will provide support for pathogenesis studies and for determination of vaccine efficacy following challenge of immunized animals. Numerous purified proteins and peptides are required in the study of retroviruses and retroviral vaccines, and these will be provided by the protein biochemistry segment of the contract. Molecular biologic capabilities will provide quantitative analytical support of vaccine and pathogenesis studies as well as direct provision of critical nucleic acid reagents. Finally, the difficulty of acquiring rhesus macaques for pre-clinical studies has necessitated including the task for locating, screening, and purchasing macaques for studies conducted by the BRL investigators. This requirement includes arranging for holding of newborn macaques until they are of sufficient age and size for experimental protocols. An offeror must meet the mandatory qualification criteria which require the offeror to have or provide evidence that they can establish biocontainment facilities (BL2 with BL3 capability) to conduct work with humana retroviruses and non-human primate retroviruses (HIV, SIV, SHIV, SIV), adenovirus and poxviruses. Offerors must also be able to supply resh, viable cells and biologically active purified proteins to the Government within one hour after harvest or preparation. Offerors must also be able to receive from the Government within one hour after harvest or collection, fresh, viable cells and tissues from primates maintained by the Government. Failure to meet the mandatory qualification will be grounds for exclusion from further consideration. The NAICS Code is 541940 with a small business size standard of 500 employees. The RFP will be be issued on or about April 5, 2004 and proposls will be due on May 10, 2004. It is anticipated that one cost-reimbursement, completion type contract, with award term provisions, for a period of five years will be awarded. This is a recompetition of contract N02-RC-91017 currently held by Advanced Biosciences Laboratory of Kensington, Maryland. The RFP will only be available electronically and may be accessed through the NCI's RCB homepage at http://rcb.nci.nih.gov. POTENTIAL OFFERORS ARE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE RFP AND ANY AMENDMENTS. COLLECT CALLS WILL NOT BE ACCEPTED.
 

Place of Performance

Address: National Cancer Institute, Bethesda, Marland

Zip Code: 20892

Country: USA
 

Record

SN00551435-W 20040324/040322211846 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |